References
- Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci 2023; 11: 42. doi: 10.3390/medsci11020042
- Shinomiya H, Nibu KI. Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma. Int J Clin Oncol 2023; 28: 975–81. doi: 10.1007/s10147-023-02336-8
- Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 2023; 8: 70. doi: 10.1038/s41392-023-01332-8
- Martens RM, Noij DP, Ali M, Koopman T, Marcus JT, Vergeer MR, et al. Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review. Oral Oncol 2019; 88: 75–83. doi: 10.1016/j.oraloncology.2018.11.005
- Bos P, van der Hulst HJ, van den Brekel MWM, Schats W, Jasperse B, Beets-Tan RGH, et al. Prognostic functional MR imaging parameters in head and neck squamous cell carcinoma: a systematic review. Eur J Radiol 2021; 144: 109952. doi: 10.1016/j.ejrad.2021.109952
- Kikuchi R, Kikuchi Y, Tsuda H, Maekawa H, Kozaki K, Imoto I, et al. Expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer. Hum Cell 2014; 27: 121–8. doi: 10.1007/s13577-014-0092-0
- Bran B, Bran G, Hörmann K, Riedel F. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated antiangiogenetic therapy in head and neck cancer. Int J Oncol 2009; 34: 255–61. doi: 10.3892/ijo_00000147
- Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 2002; 27: 32–7. doi: 10.1046/j.0307-7772.2001.00519.x
- Huang C, Zhou X, Li Z, Liu H, He Y, Ye G, et al. Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma. Mol Med Rep 2016; 14: 2489–96. doi: 10.3892/mmr.2016.5580
- Demšar J, Curk T, Erjavec A, Gorup Č, Hočevar T, Milutinovič M et al. Orange: Data Mining Toolbox in Python. J Mach Learn Res. 2013; 14: 2349–2353.
- McKinney W. Data structures for statistical computing in Python. Proceedings of the 9th Python in Science Conference, 2010; 51–56.
- Hunter J D Matplotlib: A 2D Graphics Environment. Comput Sci Eng 2007; 9(3), 90–95.
- Virtanen P, Gommers R, Oliphant T E, Haberland M, Reddy T, Cournapeau D, et. al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nature Methods 2020; 17(3), 261–272.
- Bernstein JM, Homer JJ, West CM. Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: potential to guide treatment? A systematic review. Oral Oncol 2014; 50: 963–70. doi: 10.1016/j.oraloncology.2014.07.011
- Dijkhoff RAP, Beets-Tan RGH, Lambregts DMJ, Beets GL, Maas M. Value of DCE-MRI for staging and response evaluation in rectal cancer: a systematic review. Eur J Radiol 2017; 95: 155–68. doi: 10.1016/j.ejrad.2017.08.009
- Ng SH, Liao CT, Lin CY, Chan SC, Lin YC, Yen TC, et al. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol 2016; 26: 4162–72. doi: 10.1007/s00330-016-4276-8
- Chan SC, Cheng NM, Hsieh CH, Ng SH, Lin CY, Yen TC, et al. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget 2017; 8: 62606–21. doi: 10.18632/onco-target.15904
- Ng SH, Lin CY, Chan SC, Yen TC, Liao CT, Chang JT, et al. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One 2013; 8: e72230. doi: 10.1371/journal.pone.0072230
- Baer AH, Hoff BA, Srinivasan A, Galbán CJ, Mukherji SK. Feasibility analysis of the parametric response map as an early predictor of treatment efficacy in head and neck cancer. Am J Neuroradiol 2015; 36: 757–62. doi: 10.3174/ajnr.A4296
- Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, et al. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. Eur J Nucl Med Mol Imaging 2018; 45: 759–67. doi: 10.1007/s00259-017-3890-2
- Yamazaki T, Young KH. Effects of radiation on tumor vasculature. Mol Carcinog 2022; 61: 165–72. doi: 10.1002/mc.23360
- Bisdas S, Seitz O, Middendorp M, Chambron-Pinho N, Bisdas T, Vogl TJ, et al. An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer. Eur Radiol 2010; 20: 2358–66. doi: 10.1007/s00330-010-1803-x
- Galbraith SM. MR in oncology drug development. NMR Biomed 2006; 19: 681–9. doi: 10.1002/nbm.1093
- Lowry M, Zelhof B, Liney GP, Gibbs P, Pickles MD, Turnbull LW. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue. Invest Radiol 2009; 44: 577–84. doi: 10.1097/RLI.0b013e3181b4c1fe
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74. doi: 10.1016/j.cell.2011.02.013
- Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978–85. doi: 10.1038/sj.bjc.6603923
- Macedo F, Ladeira K, Longatto-Filho A, Martins SF. Gastric cancer and angiogenesis: is VEGF a useful biomarker to assess progression and remission? J Gastric Cancer 2017; 17: 1–10. doi: 10.5230/jgc.2017.17.e1
- Liu B, Gao H, Zhou F, Zhao W, Yang Y. Dynamic contrast-enhanced magnetic resonance imaging in cervical cancer: correlation between quantitative parameters and molecular markers hypoxia-inducible factors-1-alpha, vascular endothelial growth factor, and Ki-67. Clin Radiol 2024; 79: e826–e33. doi: 10.1016/J.CRAD.2024.01.039
- Di N, Cheng W, Jiang X, Liu X, Zhou J, Xie Q, et al. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study. J Neuroradiol 2019; 46: 186–92. doi: 10.1016/j.neurad.2018.04.008
- Lindgren A, Anttila M, Arponen O, Rautiainen S, Könönen M, Vanninen R, et al. Prognostic value of preoperative dynamic contra st-enhanced magnetic resonance imaging in epithelial ovarian cancer. Eur J Radiol 2019; 115: 66–73. doi: 10.1016/j.ejrad.2019.03.023
- Keil VC, Pintea B, Gielen GH, Hittatiya K, Datsi A, Simon M, et al. Meningioma assessment: kinetic parameters in dynamic contrast-enhanced MRI appear independent from microvascular anatomy and VEGF expression. J Neuroradiol 2018; 45: 242–8. doi: 10.1016/j.neurad.2018.01.050
- Kulapaditharom B, Boonkitticharoen V, Sritara C. Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma. J Oncol 2012; 2012: 687934. doi: 10.1155/2012/687934
- Siemert J, Wald T, Kolb M, Pettinella I, Böhm U, Pirlich M, et al. Pretherapeutic VEGF level in plasma is a prognostic bio-marker in head and neck squamous cell carcinoma (HNSCC). Cancers 2021; 13: 3781. doi: 10.3390/cancers13153781
- Dumitru CS, Raica M. Vascular endothelial growth factor family and head and neck squamous cell carcinoma. Anticancer Res 2023; 43: 4315–26. doi: 10.21873/anticanres.16626
- Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006; 21: 262–8. doi: 10.1093/humrep/dei308